A 2025 review found obesity is a chronic disease of excess dysfunctional adipose tissue and chronic inflammation linked to T2D, CVD, and metabolic syndrome. A weight-inclusive precision approach is supported by pharmacological and lifestyle intervention evidence.
Did you know?
While GLP-1 receptor agonists have established efficacy in obesity, dual agonism of both GIP and GLP-1 receptors has demonstrated superior weight loss in Phase 3 trials. The SURMOUNT-1 trial (n=2,539 adults with obesity without diabetes) found that the highest approved dose of tirzepatide achieved a mean body weight reduction of 22.5% from baseline over 72 weeks, compared to 2.4% with placebo (p<0.001) — the largest weight loss effect observed in any pharmacological obesity trial to date, approaching surgical outcomes.
As dual GIP/GLP-1 agonism achieves weight loss that approaches bariatric surgery outcomes, how is this changing your treatment algorithm for severe obesity — and how are you addressing the anticipated long-term therapy duration needed to maintain weight loss?
Source : https://pubmed.ncbi.nlm.nih.gov/42726073
Clinical inertia is prevalent in managing cardiovascular risk in primary care, leading to smaller reductions in cholesterol levels, but not affecting glycaemic parameters or triglycerides.
Clinical inertia affects over half of high-risk patients with uncontrolled hypertension, diabetes, or dyslipidaemia, leading to smaller reductions in total and LDL cholesterol.
Did you know? Obesity is a chronic, relapsing neurobiological disease driven by dysregulation of appetite-regulating hormones and energy homeostasis. GLP-1 receptor agonism reduces caloric intake centrally and slows gastric emptying. In the STEP 1 trial, once-weekly semaglutide achieved sustained weight reductions with many patients losing more than 15% of body weight, along with meaningful improvements in cardiometabolic risk factors.
How has your framing of obesity as a chronic disease changed how you discuss treatment goals with patients?
How has your framing of obesity as a chronic disease changed how you discuss treatment goals with patients?
Obesity is increasingly recognized as a chronic inflammatory condition associated with altered metabolic signaling, insulin resistance, and systemic health complications. Growing evidence supports the importance of early, sustained approaches to long-term weight management.